DelveInsight’s “Prostate Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Prostate Cancer Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Prostate Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Prostate Cancer: An Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of the male reproductive system. Prostate cancer is the 3rdmost prevalent type of cancer in the US and the fourth most common worldwide.
Approximately one in nine men in the United States will be diagnosed with prostate cancer at some point in their lives. Furthermore, as per American Cancer Society (2019), prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.
Treatment options for prostate cancers include mainly hormonal therapies (also known as androgen-deprivation therapy or ADT), chemotherapy, immunotherapy, radiation therapy, and surgery. For localized or locally advanced prostate cancer, active surveillance, surgery, and radiation therapy are the three major treatment options.
Prostate Cancer Market Key Facts
The total prevalent cases of Prostate Cancer in the 7MM were observed to be 6,742,385 in 2017, and are expected to increase in the coming years.
The highest number of prevalent cases was observed in the United States, with 3,170,339 cases in 2017.
According to DelveInsight’s analysis, nearly 60 percent of Prostate Cancer cases are diagnosed during localized or locally advanced stages (Stage I-III) in the United States.
Among the EU-5 countries, the highest number of diagnosed prevalent cases of prostate cancer was found in Germany with 360,916 cases in 2017, followed by France and Italy.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Prostate Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Prostate Cancer market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Prostate Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Prostate Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prostate Cancer market or expected to get launched during the study period. The analysis covers Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/prostate-cancer-market
Prostate Cancer Therapeutics Analysis
The available therapeutics treatment options in the Prostate Cancer Landscape aim to provide cures to the patients suffering from this indication. However, there are several challenges that are yet to be tackled.
As per DelveInsight, the dynamics of the Prostate Cancer market are anticipated to change in the coming years owing to the rise in the number of companies taking an interest in developing therapies for Prostate Cancer. There are approx. 200+ key companies which are developing therapies for Prostate Cancer. Currently, Merck & Co. has its Prostate Cancer drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Prostate Cancer Therapeutics Market include:
Merck & Co, Pfizer, Orionl, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and many others
Prostate Cancer Therapies covered in the report include:
Lynparza, Opdivo, Lutathera, Relugolix, Niraparib, Ipatasertib, ProstAtak, Keytruda, Rucaparib, Pembrolizumab, Talazoparib, ODM-208, ZEN 3694, EPI-7386, and many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/prostate-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Prostate Cancer Competitive Intelligence Analysis
4. Prostate Cancer Market Overview at a Glance
5. Prostate Cancer Disease Background and Overview
6. Prostate Cancer Patient Journey
7. Prostate Cancer Epidemiology and Patient Population
8. Prostate Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Prostate Cancer Unmet Needs
10. Key Endpoints of Prostate Cancer Treatment
11. Prostate Cancer Marketed Products
12. Prostate Cancer Emerging Therapies
13. Prostate Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Prostate Cancer Market Outlook (7 major markets)
16. Prostate Cancer Access and Reimbursement Overview
17. KOL Views on the Prostate Cancer Market.
18. Prostate Cancer Market Drivers
19. Prostate Cancer Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/prostate-cancer-market
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Myofascial Pain Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Myofascial Pain Syndrome Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States